WO2021001044A1
|
|
Process for the preparation of key intermediates for the synthesis of eltrombopag or salt thereof
|
EP3604284A1
|
|
Crystalline eltrombopag monoethanolamine salt form d
|
EP3604285A1
|
|
Highly stable crystalline form d1 of the eltrombopag monoethanolamine salt
|
EP3594199A1
|
|
Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof
|
EP3587393A1
|
|
Enzymatic process for the preparation of droxidopa
|
EP3560934A1
|
|
Process for the preparation of pure 2-cyanophenylboronic acid and esters thereof, intermediates of perampanel or of e2040
|
EP3524605A1
|
|
New efficient process for the preparation of sitagliptin
|
EP3450567A1
|
|
Process for the preparation of (r)-beta-angelica lactone from alpha-angelica lactone employing ene-reductases
|
EP3424927A1
|
|
Efficient process for the preparation of sitagliptin through a very effective preparation of the intermediate 2,4,5-trifluorophenylacetic acid
|
EP3421455A1
|
|
Improved process for the preparation of chiral 3-amino-piperidins, useful intermediates for the preparation of tofacitinib
|
EP3404025A1
|
|
Process for the preparation of pure nilotinib and its salt
|
EP3360865A1
|
|
Process for the preparation of cyclopropyldiketopiperazines, and of a key intermediate of ds-5272
|
US10047094B1
|
|
Process for the preparation of triazole and salt thereof
|
CN107614496A
|
|
The method for preparing amino tetrahydro pyran compound
|
CN107840823A
|
|
For the method for the scalable for preparing Sorafenib Tosylate alcohol solvent compound and III type Sorafenib Tosylates
|
EP3266773A1
|
|
Process for the preparation of lapatinib ditosylate monohydrate by means of an improved crystallization procedure
|
CN105392772A
|
|
Process for the preparation of key intermediates of omarigliptin
|
AU2013286077A1
|
|
Process for preparing enantiomerically enriched oxamides
|
EP2551268A1
|
|
Process for the preparation of moxifloxacin hydrochloride and intermediates thereof
|
BR112013023130A2
|
|
ASYMMETRIC REDUCTION PROCESS
|